Live Breaking News & Updates on ஏ ராய் டோர்ஸி

Stay updated with breaking news from ஏ ராய் டோர்ஸி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Letter: More research needed on sources of Parkinson's disease


Editor of the Reformer:
Dear Legislative Leaders,
In May of 2016 I was diagnosed with Parkinson’s disease. Since them I have witnessed a degradation in mobility and cognitive functioning. I am fortunate to be living in a time where drugs and exercise have a combined effect at slowing the disease’s progression; however, no cure exists.
With the above in mind I would like the state of Vermont to begin the collection of data as it relates to the tracing of Parkinson’s. As outlined in “The Rise of Parkinson’s Disease” (E. Ray Dorsey, Todd Sherer, Michael S. Okun, Bastiaan R. Bloem for American Scientist) research reveals the rise of Parkinson’s in rural areas likely elevated by the presence of the following: paraquat, rotenone and trichlorethylene. The first two are used in agricultural applications while the latter is used in “washing away grease, cleaning silicon wafers, removing spots in dry cleaning.” Current evidence exists ....

United States , Craftsbury Common , Todd Sherer , John Zaber , Michaels Okun , E Ray Dorsey , Bastiaanr Bloem , Legislative Leaders , American Scientist , ஒன்றுபட்டது மாநிலங்களில் , கைவினை பொதுவானது , டாட் ஷெரர் , ஜான் ஜபெர் , மைக்கேல்ஸ் ஓக்குங் , ஏ ராய் டோர்ஸி , சட்டமன்றம் தலைவர்கள் , அமெரிக்கன் விஞ்ஞானி ,

Eisai to Launch Parkinson's Disease Treatment Equfina in South Korea


Eisai to Launch Parkinson s Disease Treatment Equfina in South Korea
TOKYO, Feb 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai s subsidiary in South Korea, has launched the Parkinson s disease treatment Equfina (safinamide mesilate, safinamide ). This is the first launch of Equfina in the Asian region excluding Japan.
The estimated number of patients with Parkinson s disease is approximately 150,000 in South Korea. Parkinson s disease has high unmet medical needs because of inadequate symptom control using current medications, necessitating new treatment options. This disease is designated as a rare intractable disease in South Korea.
The marketing approval of this drug in South Korea is primarily based on a double-blind, placebo-controlled, Phase III Study (SETTLE study) conducted overseas (including South Korea) to evaluate the efficacy and safety of 24-week oral administration of the once-daily safinamide as an add-on to lev ....

United States , Hong Kong , Republic Of , South Korea , E Ray Dorsey , Japanese Society Of Neurology Parkinson , Newron Pharmaceuticals , Eisai Co Ltd , Public Relations Department , Eisai Korea Inc , Meiji Seika Pharma Co Ltd , Japan Intractable Diseases Information Center , Levodopa Adjunct , Patients With Parkinson Disease , Motor Fluctuations , Randomized Clinical , Global Burden , Disease Study , Japanese Society , Relations Department , ஒன்றுபட்டது மாநிலங்களில் , ஹாங் காங் , குடியரசு ஆஃப் , தெற்கு கொரியா , ஏ ராய் டோர்ஸி , ஜப்பானிய சமூகம் ஆஃப் நரம்பியல் பார்கின்சன் ,